干扰素介导的抗肿瘤新生血管形成作用
被引量:4
The effect of interferon mediated antiangiogenesis on tumor therapy
摘要
机体抗血管形成的主要因子之一是β-干扰素 (IFN -β)。经常 (或每日 )应用低剂量 IFN (α或β)或直接将 IFN-β基因转导到肿瘤细胞内 ,在一些临床前原位肿瘤模型中已经显示出显著的疗效。对干扰素抗血管形成作用的进一步认识 。
出处
《国外医学(肿瘤学分册)》
2001年第1期14-17,共4页
Foreign Medical Sciences (Cancer Section)
参考文献10
-
1Johns TG,Mackay IR,Callister KA,et al.Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta[].Journal of the National Cancer Institute.1992
-
2Abramovich C,Shulman LM,Ratovitski E,et al.Differential tyrosine phosphorylation of the IFNAR chain of the type Ⅰ interferon receptor and of an associated surface protein in response to IFN-alpha and IFNbeta[].EMBO Journal.1994
-
3Dong Z,Greene G,Pettaway C,et al.Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon beta[].Cancer Research.1999
-
4White CW,Sondheimer HM,Crouch EC,et al.Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a[].The New England Journal of Medicine.1989
-
5Dinney CP,Bielenberg DR,Reich R,et al.Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration[].Cancer Research.1998
-
6Singh RK,Gutman M,Bucana CD,et al.Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas[].Proceedings of the National Academy of Sciences of the United States of America.1995
-
7Stout AJ,Gresser I,Thompson WD.Inhibition of wound healing in mice by local interferon alpha beta injection[].International Journal of Experimental Pathology.1993
-
8Negrier S,Escudier B,Lasset C,et al.Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma[].The New England Journal of Medicine.1998
-
9Hong YK,Chung DS,Joe YA,et al.Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development[].Clinical Cancer Research.2000
-
10Bielenberg DR,Fidler IJ,Bucana CD.Constitutive expression of interferon beta in differentiated epithelial cells exposed to environmental stimuli[].Cancer Biotherapy and Radiopharmaceuticals.1998
同被引文献33
-
1孙春艳,胡豫,吴涛,王雅丹,何文娟.多发性骨髓瘤细胞脑源性神经营养因子对血管新生作用的研究[J].中华血液学杂志,2005,26(10):602-606. 被引量:13
-
2Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000 ;96 ( 6 ) :2240 - 2245.
-
3Livak K J, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-△△cT method. Methods, 2001 ;25:402-408.
-
4Verstosck S, Kantarjian H, Manshoufi T, et al. Progonostic significance of ceUeular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood, 2002 ;99 (6) : 2265 - 2267.
-
5Xiao Z, Wang Y, Lu L, et al. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leuk Res. 2006;30( 1 ) :54 -59.
-
6Di Raimondo F, Palumbo GA, Molica S, et al. Acta Haematol, 2001 ; 106(4) : 177 - 183.
-
7Wang L, Tang ZY, Qin LX, et al. High-dose and long-term therapy with interferon-alfa inhibits turner growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potenial. Hepatology, 2000 ;32 ( 1 ) :43 - 48.
-
8Wu WZ, Sun HC, Shen YF, et al. Interferon alpha 2a down- regulating VEGF expression through P13 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol, 2005 ; 131 ( 3 ) : 169 - 178.
-
9汤地,梁力建,彭宝岗,周凡,李绍强,殷晓煜.IFN-α抑制HUVECs以及荷人肝癌裸小鼠血管生成的实验研究[J].中国病理生理杂志,2007,23(8):1495-1498. 被引量:6
-
10司徒镇强 吴军正.细胞培养[M].西安:世界图书出版公司,2004.239-245.
引证文献4
-
1贾喜花,唐汉钧.乳宁Ⅱ号对乳腺癌术后患者血清中VEGF TNF-aINF-r影响的研究[J].中医药学刊,2005,23(8):1430-1431. 被引量:6
-
2陈卫昌,刘强,陈桂林,康苏娅,马文雄.血管内皮抑素转基因口服制剂联合5-Fu、IFN-α 2a治疗结肠癌的实验研究[J].苏州大学学报(医学版),2006,26(4):556-560.
-
3张利铭,虞咏知,黄知平,张万胜,董莉.干扰素-α2b对慢性髓系白血病抗血管生成作用的体外研究[J].中国实验血液学杂志,2010,18(2):291-295. 被引量:3
-
4张鲁文.肿瘤血管生成抑制剂的研究进展[J].实用医技杂志,2002,9(10):802-803.
二级引证文献9
-
1罗崇谦,黄霖.中医药治疗乳腺癌[J].湖北中医杂志,2006,28(4):42-43. 被引量:8
-
2杨杰,高锋,孙洋,丁维俊,王米渠.中药抗癌的分子药效探讨[J].中华中医药学刊,2007,25(3):577-579. 被引量:3
-
3祁明浩,徐力.乳腺癌防转移的中医现代研究进展[J].现代中医药,2010(1):66-68. 被引量:3
-
4贾喜花,王运良,刘勇,马旭东,耿淑美,张晓伟.“乳宁Ⅱ号”防治乳腺癌术后放射性肺炎63例临床研究[J].江苏中医药,2011,43(2):23-24. 被引量:6
-
5薛晓红,江科,李琼,裴建遇,黎伟,陆清.乳腺癌患者治疗前后血清VEGF动态变化及乳癌术后方的干预作用[J].上海中医药杂志,2011,45(6):46-48. 被引量:4
-
6韦金华,韦爱芳,张发恩,韦亚娜,韦嵩.羟基脲加干扰素α-2b治疗慢性粒细胞白血病慢性期的疗效分析[J].中外医疗,2013,32(31):96-96. 被引量:3
-
7龙彬彬.羟基脲加干扰素α-2b治疗慢性粒细胞白血病慢性期的临床研究进展[J].中国民族民间医药,2014,23(19):26-27. 被引量:1
-
8余东阳,项著星,孙军,张大林,韩丽蓉,郭飞波,宋江勤.PTD4-GFP-Apoptin 融合蛋白对白血病细胞增殖与凋亡的影响[J].白血病.淋巴瘤,2016,25(10):577-581. 被引量:1
-
9张帅,刘胜.顾氏外科乳腺癌治验[J].吉林中医药,2017,37(3):241-244. 被引量:12
-
1李宏江,赵扬冰.抗肿瘤新生血管形成治疗实体肿瘤的研究进展[J].中国普外基础与临床杂志,2002,9(3):207-209. 被引量:7
-
2张润玲,赵进昌.卵巢肿瘤患者血管内皮生长因子表达及其检测[J].国外医学(临床生物化学与检验学分册),2001,22(6):289-289.
-
3尚双艳,冯义朝.MMP-2、MMP-9和VEGF与胃癌的研究进展[J].中国医药指南,2012,10(21):78-80. 被引量:1
-
4孙希才,葛荣明,董庆汉,郑传铭.环氧化酶-2在喉鳞状细胞癌中的表达及其与微血管密度的关系[J].临床耳鼻咽喉科杂志,2005,19(21):967-970. 被引量:9
-
5杨蓉,孙萍,宋芳霞,王建.干扰素介导的跨膜蛋白1与卵巢上皮性癌耐药相关性研究[J].现代肿瘤医学,2015,23(10):1428-1431. 被引量:2
-
6常茹,李莉.反应停抗肿瘤及对生活质量的影响[J].健康必读(下),2010,1(8):128-128.
-
7李晓明.抗血管形成药物临床应用进展[J].国外医学(肿瘤学分册),1998,25(3):137-139. 被引量:1
-
8牛牛,李宝兰.内皮抑素抗肿瘤机制和应用的研究进展[J].医学综述,2012,18(23):3963-3965. 被引量:3
-
9杨蓉,孙萍,宋芳霞,李佩,王建.干扰素介导的跨膜蛋白1在卵巢上皮性癌中的表达[J].中国妇幼健康研究,2015,26(2):240-243.
-
10王含必,郎景和.鸡胚绒毛尿囊膜在抗血管形成研究中的应用[J].国外医学(妇产科学分册),2005,32(5):296-298. 被引量:2